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Abstract
Background: Breast cancer is worldwide the second most common type of cancer after lung cancer. Traditional
mammography and Tissue Microarray has been studied for early cancer detection and cancer prediction. However, there
is a need for more reliable diagnostic tools for early detection of breast cancer. This can be a challenge due to a number
of factors and logistics. First, obtaining tissue biopsies can be difficult. Second, mammography may not detect small
tumors, and is often unsatisfactory for younger women who typically have dense breast tissue. Lastly, breast cancer is not
a single homogeneous disease but consists of multiple disease states, each arising from a distinct molecular mechanism
and having a distinct clinical progression path which makes the disease difficult to detect and predict in early stages.
Results: In the paper, we present a Support Vector Machine based on Recursive Feature Elimination and Cross
Validation (SVM-RFE-CV) algorithm for early detection of breast cancer in peripheral blood and show how to use SVM-
RFE-CV to model the classification and prediction problem of early detection of breast cancer in peripheral blood.
The training set which consists of 32 health and 33 cancer samples and the testing set consisting of 31 health and
34 cancer samples were randomly separated from a dataset of peripheral blood of breast cancer that is
downloaded from Gene Express Omnibus. First, we identified the 42 differentially expressed biomarkers between
“normal” and “cancer”. Then, with the SVM-RFE-CV we extracted 15 biomarkers that yield zero cross validation
score. Lastly, we compared the classification and prediction performance of SVM-RFE-CV with that of SVM and SVM
Recursive Feature Elimination (SVM-RFE).
Conclusions: We found that 1) the SVM-RFE-CV is suitable for analyzing noisy high-throughput microarray data, 2)
it outperforms SVM-RFE in the robustness to noise and in the ability to recover informative features, and 3) it can
improve the prediction performance (Area Under Curve) in the testing data set from 0.5826 to 0.7879. Further
pathway analysis showed that the biomarkers are associated with Signaling, Hemostasis, Hormones, and Immune
System, which are consistent with previous findings. Our prediction model can serve as a general model for
biomarker discovery in early detection of other cancers. In the future, Polymerase Chain Reaction (PCR) is planned
for validation of the ability of these potential biomarkers for early detection of breast cancer.
Background
Breast cancer is the most common type of cancer among
women in the United States [1]. Early detection is key to
the successful treatment of breast cancer. Traditional
methods most used for early detection have been regular
and periodic self examination and annual or biannual
check-ups using mammography and analysis of tissue
biopsies. However, early cancer detection and treatment
are still challenging. One reason is that mammography as
a screening tool for early detection has many drawbacks.
For example, mammography may not detect small
tumors, and is often unsatisfactory for younger women,
who typically have dense breast tissue. Another reason is
that obtaining tissue biopsies can be difficult for reasons
including small size of lump, lack of available medical
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facilities, and patients’ reluctance to undergo invasive
procedures due to potential scaring and financial costs.
Moreover, the fact that breast cancer is not a single
homogeneous disease but consists of multiple disease
states, each arising from a distinct molecular mechanism
and having a distinct clinical progression path [2], makes
the disease difficult to detect in early stages.
To address these issues, a novel and minimally invasive
test that uses easily obtained peripheral blood for breast
cancer detection has been developed [3,4]. For example,
Sharma et al. used microarrays and nearest-shrunken-cen-
troid method to analyze the expression pattern of 1,368
genes in peripheral blood cells of 24 women with breast
cancer and 32 women with no sign of this disease. The
study found that a blood-based gene expression test can
be developed to detect breast cancer early in asympto-
matic patients [4]. Aaroe et al. collected peripheral blood
from 67 breast cancer samples and 63 normal samples,
identified a set of 738 differentially expressed probes, and
achieved an estimated prediction accuracy of 79.5% with a
sensitivity of 80.6% and a specificity of 78.3% [3].
There is a need for more reliable diagnostic tools for
early detection of breast cancer in peripheral blood which
can achieve high prediction accuracy with as few genes as
possible, and to reduce the required examination of a
large number of genes which increases the dimensionality,
computational complexity, and clinical cost of diagnosis
[5].
Support Vector Machine Recursive Feature Elimination
(SVM-RFE) approach for gene selection proposed by
Guyon [6] is one of the most effective feature selection
methods which has been successfully used in selecting
informative genes for cancer classification. It is a backward
selection approach that selects genes according to their
influence (weight) on a support vector machine. First it
calculates ranking criteria based on the SVM weights.
Then it eliminates features with the smallest ranking cri-
terion. Lastly it repeats the process until a highest classifi-
cation accuracy is achieved.
SVM-RFE is used to find discriminate relationships
within clinical datasets and within gene expression data-
sets created from micro-arrays of tumor versus normal tis-
sues. However, the feature elimination method is sensitive
to small perturbations of the training set. The features it
extracts from training set might not have good prediction
performance in an independent testing set. This is prob-
ably caused by overfitting which arises when 1) the num-
ber of features is large and the number of training patterns
is comparatively small or 2) some regularities appear in
the training data that do not appear in the test data. In
order to avoid the overfitting and gain best prediction
accuracy for the testing set, we built an SVM based on
Recursive Feature Elimination and Cross Validation
(SVM-RFE-CV) to extract optimal features.
We propose for the first time a multi-marker panel
development solution for early detection of breast can-
cer in peripheral blood by using a SVM-RFE-CV, and
show how to use SVM-RFE-CV to model the classifica-
tion and prediction problem of early detection of breast
cancer in peripheral blood.
We compared the classification and prediction perfor-
mance of SVM-RFE-CV with that of SVM and SVM
Recursive Feature Elimination (SVM-RFE) and found
that 1) the SVM-RFE-CV is suitable for analyzing noisy
high-throughput microarray data, 2) it outperforms
SVM-RFE in the robustness to noise and in the ability
to recover informative features, and 3) it can improve
the prediction performance (Area Under Curve) in the
testing data set from 0.5826 to 0.7879.
Materials and methods
Peripheral blood data collection
We downloaded the 130 samples of peripheral blood
data through the GEO database, which are publically
available with the accession number GSE16443 [3] and
were collected to originally determine the potential of
gene expression profiling of peripheral blood cells for
early detection of blood cancer. It consists of 130 sam-
ples with 67 cases and 63 controls. We randomly
divided the 130 samples into two groups: group A as a
training set and group B as a testing set (Table 1).
Normalization
Normalization per sample was used to normalize the
data. First, log ratio base 2 transformation was used to
transform the data. And then for each probe the median
of the log summarized values from all the samples were
calculated and subtracted from each of the samples.
Linear mixed model
We used the ABI Human Genome Survey Microarray
Version 2 to manage and map probe IDs. A full factorial
model was used to represent the fixed effect and the
random effect which are used to account for group and
probe. The expression log ratios value is the final quan-
tity that is fit by a separate analysis of the variance
(ANOVA) statistical model for each probe as yil using
the following:
yij = μ + Ti + Sj + εij
Table 1 statistics of samples
#health #cancer #total
Training set 32 33 65
Testing set 31 34 65
Total 63 67 130
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where Sj ∈ N(0, σ 21 ) , εij Î N(0, s2). Here, μ is the
mean expression value, Ti is the fixed group effect
(caused by the experimental conditions or treatments
being evaluated), Sj is the random sample effect (random
effects from either individual biological samples or sam-
ple preparations), and εij is the within-groups errors. All
random effects are assumed independent of each other
and independent of the within-groups errors εij.
Statistics
Statistical Significance was measured by a three-step
method. First, we conducted the above linear mixed
model to obtain the p value of the significance for the
group effect. Then we calculated the FDR adjusted p
value. Lastly, we calculated the FDR q value using the
Storey-Tibshirani method [7]. We chose a significance
screening filter (q < 0.01) to select genes of which we esti-
mated significant differences in the health and breast can-
cer samples. The False Positive Rate (FPR), or expected
proportion of false positive among the proteins with
declared changes, is FPR = qvalue × number of the genes
with declared changes.
Support Vector Machine
The classification problem of breast cancer can be
restricted to consideration of the two-class problem
without loss of generality (breast cancer and normal).
We developed a Support Vector Machine Recursive Fea-
ture Elimination(SVM-RFE) method [6] based on Cross-
Validation (CV) (SVM-RFE-CV) to eliminate features
for breast cancer from peripheral blood. And then we
built a classifier based on the selected features and
applied the classifier to predict breast cancer from per-
ipheral blood in an independent testing set.
Consider the problem of separating the set of training
patterns belonging to two separate classes (1, breast cancer;
-1, normal), D = {(x1, y1),..., (x1, y1)}, x Î ℝ
n, yÎ {-1, 1} with
a hyperplane <w, × > + b = 0. The set of patterns is said to
be optimally separated by the hyperplane if it is separated
without error and the distance between the closest pattern
to the hyperplane is maximal. Without loss of generality it
is appropriate to consider a canonical hyperplane [8],
where the parameters w, b are constrained by
min
i
| < w, xi > +b| = 1 . That is, the norm of the weight
vector should be equal to the inverse of the distance, of the
nearest point in the data set to the hyperplane. A separat-
ing hyperplane in canonical form must satisfy the following
constraints: yi[<w, xi > +b] ≥ 1 - ei, i = 1, ..., l. Therefore,
according to the structural risk minimization inductive
principle, the training of an SVM is to minimize the guar-












subject to the constraints yi[<w, xi > + b] ≥ 1 - ei, i = 1, ..., l.
The above optimization problem can be used in a lin-
ear recognition problem, but in this case, the classifica-
tion problem is nonlinear. To solve the nonlinear
classification problem, we can map first the training
data to another feature space F via a nonlinear map :
ℝn ® F and then perform the above computations in F.
We used Gaussian radius basis function (RBF) kernels
function for SVM.
Recursive feature elimination(SVM-RFE) method based on
cross-validation
SVM-RFE was introduced by Guyon et al. for selecting
genes from microarray data analysis for cancer classifi-
cation [6]. It includes four steps: 1) Train an SVM on
the training set; 2) calculate ranking criteria based on
the SVM weights; 3) Eliminate features with the smallest
ranking criterion; and 4) Repeat the process. The feature
elimination method is sensitive to small perturbations of
the training set. The features it extracts from training
set might not have good prediction performance in an
independent testing set. Therefore, we adopted leave-
one-out cross validation method to improve the stability
and robustness of SVM-RFE. In addition, we chose |W|
as ranking criteria instead of W2 in the SVM-RFE-CV
algorithm. The SVM-RFE [6] chose Ci = W2i as ranking
criteria and eliminates the feature with smallest ranking
criterion. The original optimization equation in SVM
actually depends on the absolute value of weight |W|.
Substituting 12W
2 for |W| can change the non-convex
optimization to a quadratic programming optimization
which is more easy to solve mathematically. But when
we loop the feature elimination based on leave-one-out
cross-validation, 12W
2 loses its advantages over |W| on
convexity of optimization. And |W| has bigger ranking
criteria than 12W
2 , which makes optimization selection
more accurate. Therefore, we chose |W| as ranking cri-
teria in the SVM-RFE-CV algorithm.
The SVM Recursive Feature Elimination method
based on Cross-Validation (SVM-RFE-CV) is described
as follows:
k = K; #Select All features
for (i in 1:n) #n is the sample size
{
Build a SVM using the ith sample as testing set and
others as training set;
Calculate the feature weight Wi and the error rate Ei;
}
Sum up weights: W = sum(abs(Wi));
Sum up error rates: E = sum(Ei);
E0 = E;
while (E < = E0)
{
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E0 = E;
rkw = rank(W); #rank the feature score
k = k[which(rkw > 1)]; # remove features with lowest
feature score
for (i in 1:n)
{
Build a SVM using the ith sample as testing set
and others as training set;
Calculate the feature weight Wi and the error rate
Ei;
}
Sum up weights: W = sum(abs(Wi));
Sum up error rates: E = sum(Ei);
}
The error rate is calculated by 1 minus accuracy. All
error rates for the n cross validations are summed up as
determination of loop iterations.
Enumeration method for validation
The enumeration method based on feed forward neural
network was built to identify optimal biomarkers panel
by us [9]. Similarly, we designed an enumeration method
based on SVM to verify whether the biomarkers panel
identified by the SVM-RFE-CV in the training set has
still best prediction performance for the testing set.
We randomly chose M combinations of N (for example
M = 100,000 when N = 15 for fifteen-marker panel) out of
all the 42 genes differentially expressed in the training set
and built M SVMs. In order to find the optimal classifier,
we presented an enumeration method that measures the
area under the curve (AUC) for Receiver Operating Char-
acteristics (ROC). First, we trained the M SVMs in the
training set with five-fold cross-validation. Then, we mea-
sured the AUC for each of the M combinations in the test-
ing set. Lastly, the combinations were ranked by
rankC = AUC(SVMC,T),
where AUC is the area under the ROC curve of SVM
prediction, SVM is the trained classifier, C is one of M
combinations of picking N out of the 42 genes, and T is
the testing set.
Cross-validation
k-fold cross-validation was used to increase the number of
estimates and improve the accuracy of the prediction
model by avoiding the over-fitting. In k-fold cross-valida-
tion, the original sample is randomly partitioned into k sub-
samples. Of the k subsamples, a single subsample is
retained as the validation data for testing the model, and
the remaining k-1 subsamples are used as training data.
The cross-validation process is then repeated k times, with
each of the k subsamples used exactly once as the validation
data. The k results from the folds then can be averaged to
produce a single estimation. The advantage of this method
over repeated random sub-sampling is that all observations
are used for both training and validation, and each observa-
tion is used for validation only once. If k equals the sample
size, this is called leave-one-out cross-validation.
Performance measurements
The following five measurements were involved in our
evaluation: (1) Sensitivity (also called recall), the propor-
tion of actual positive pairs which are correctly identi-
fied; (2) Specificity, the proportion of negative pairs
which are correctly identified; (3) Precision, the prob-
ability of correct positive prediction; (4) Accuracy, the
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Pathway analysis
We performed the pathway analysis using the databases:
Integrated Pathway Analysis Database (IPAD) http://
bioinfo.hsc.unt.edu/ipad/[10].
Results
We downloaded from the Gene Expression Omnibus
(accession number GSE16443) [3] the 130 samples with
67 breast cancer and 63 healthy women. After we ran-
domly divided the 130 samples into two groups, group
A as training set and group B as testing set (Table 1),
we obtained 32 health samples and 33 cancer samples
in the training set and 31 health samples and 34 cancer
samples in the testing set. No data from the testing set
were utilized in 1) identification of peripheral blood
markers or 2) development of the SVM model.
We obtained 42 markers in the training set with qvalue
< 0.01. An SVM model was built on all the 42 markers in
the training set. We obtained a high performance (AUC =
0.98, precision = 97.0%, accuracy = 98.4%, sensitivity =
100.0%, specificity = 96.9%) for the training set but a low
performance (AUC = 0.56, precision = 58.8%, accuracy =
56.9%, sensitivity = 58.8%, specificity = 54.8%) for testing
set (Table 2). The result shows that using all markers as a
predictor can achieve satisfactory prediction accuracy only
for training set but not for the testing set. This is probably
caused by overfitting which arises when 1) the number of
features is large and the number of training patterns is
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comparatively small or 2) some regularities appear in the
training data that do not appear in the test data. In order
to avoid the overfitting and gain best prediction accuracy
for the testing set, we built an SVM based on Recursive
Feature Elimination and Cross Validation (SVM-RFE-CV)
to extract optimal features. We show in Figure 1 the auto-
matic tuning of number of features selected with the
recursive feature elimination and the leave-one-out cross-
validation. Training of the SVM-RFE-CV was performed
using radius basis function (RBF) kernels function and
leave-one-out cross-validation. Cross-validation scores
were calculated to help evaluate the predictive perfor-
mance of features selected by SVM-RFE-CV. The cross-
validation scores is defined as number of false discovery
which can be calculated by
cross − validation score = Error Rate ∗ number of sample size.
The best cross-validation score with the least number
of features occurs when the number of features is equal
to 15 (Figure 1). The heatmap of the 15-marker panel
for the testing set is shown in Figure 2. 26 out of 32
cancer samples and 22 out of 31 normal samples were
correctly predicted.
Table 3 shows the direction and strength of expression
changes for the 15 biomarkers. Some markers and their
association with cancer already have been reported. For
example, NOD1 is a cytosolic protein that senses meso-
diaminopimelic acid-containing ligands derived from pep-
tidoglycan and plays a role in host responses to invasive
bacteria. Da et al. used Cell lines derived from the human
breast cancer epithelial cell line (MCF-7) to characterize a
pathway linking NOD1 to the growth of estrogen-sensitive
tumors in a severe combined immune deficiency (SCID)
mouse xenograft model. They found that the absence of
NOD1 correlates with tumor growth, an increased sensi-
tivity to estrogen-induced cell proliferation, and a failure
to undergo NOD1-dependent apoptosis in the MCF-7
cells and conversely, overexpression of NOD1 in MCF-7
cells results in inhibition of estrogen-dependent tumor
growth and reduction of estrogen-induced proliferative
responses in vitro [11].
Left-right determination factor 2 (LEFTY2) encodes a
member of the TGF-beta family of proteins. The encoded
protein is secreted and plays a role in left-right asymme-
try determination of organ systems during development.
The protein may also play a role in endometrial bleeding
which is one of the most common manifestations of
gynecologic diseases. Hernandez et al. found that promo-
ters of LEFTY2 were differentially methylated in breast
cancer samples relative to corresponding surrounding tis-
sue [12].
Xie et al. observed overexpression of CTGF, WISP1,
CYR61, and NOVH in primary breast tumors. They found
significant associations between WISP1 mRNA levels ver-
sus stage, tumor size, lymph node, and HER-2/neu overex-
pression with statistical univariate analysis. Their results
suggested that CTGF, WISP-1, and CYR61 might play a
role in the progression of breast cancer and might serve as
a valuable tool for monitoring tumor status of breast can-
cer patients [13]. Davies et al. analyzed the expression of
the three WISP molecules at the mRNA and protein levels
in a cohort of 122 human breast tumors and 32 normal
breast tissues, and their correlations with patients’ clinical
outcomes. WISP1 transcripts were found in lower levels in
node-positive tumors compared with node-negative
tumors (P < .05); were lower in patients with a moderate
(P = .01) and poor Nottingham Prognostic Index prog-
nosis (P < .05) compared with good prognostic groups;
were of significantly lower level in grade 3 differentiated
tumors (P < .05) compared with grade 1; and were of
lower levels in patients who developed metastasis and died
from breast cancer-related causes (P < .05 in both compar-
isons). They concluded that WISP-1 seemed to act as a
tumor suppressor, WISP-2 as a factor that stimulates
aggressiveness; and WISP-3 has no definable beneficial or
detrimental role [14].
FABP1 encodes the fatty acid-binding protein found in
liver. Hammamieh et al. showed that blocking the expres-
sion of FABP1 resulted in remarkable effects on apoptosis
and cell proliferation of prostate cancer cell lines [15] and
FABP1 and intestine fatty acid binding proteins was up-
regulated in breast cancer cell lines [16].
Sala et al. studied PLCG1 and its role in breast cancer
metastasis and discovered this gene can promote cancer
metastasis and subsequently blocking it stopped cancer
from spreading. They showed that down-regulation of
Table 2 performance comparison of SVM, SVM-RFE, and SVM-RFE-CV
Measure SVM SVM-RFE SVM-RFE-CV
#genes 42 18 15
Training set Testing set Training set Testing set Training set Testing set
Precision 97.0% 58.8% 100% 71.4% 100% 74.29%
Accuracy 98.4% 56.9% 100% 70.8% 100% 73.85%
Sensitivity 100.0% 58.8% 100% 73.5% 100% 76.47%
Specificity 96.9% 54.8% 100% 67.7% 100% 70.97%
AUC 0.98 0.56 1.0 0.75 1.0 0.80
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PLCgamma1 expression severely impaired activation of
the small GTP-binding protein Rac and cell invasion in
breast cancer cell lines and U87 in vitro. In addition, they
found an increase of PLCgamma1 expression in metasta-
sis compared with the primary tumor in 50% of 60 breast
cancer patients’ tissues analyzed. They suggested that
PLCgamma1 inhibition had a therapeutic potential in the
treatment of metastasis dissemination [17].
Arteaga et al. determined the relative content of PLC-
gamma 1 in primary human mammary carcinomas and
in nonmalignant mammary tissues. They detected con-
siderably higher levels of PLC-gamma 1 protein in the
majority of carcinomas and in one of two benign fibroa-
denomas compared to normal breast tissues by Western
blot and immunohistochemistry. They also detected the
presence of phosphotyrosine on PLC-gamma 1 in 18 of
21 carcinomas that contained high levels of PLC-gamma
1. They found that all carcinomas in which tyrosine
phosphorylated PLC-gamma 1 was present also
expressed detectable levels of the epidermal growth fac-
tor receptor or erbB-2, two tyrosine kinases known to
phosphorylate this enzyme. They concluded that
increased levels of receptor tyrosine kinases and a direct
tyrosine phosphorylation substrate could be linked with a
high percentage of mammary carcinomas and amplify
two successive steps in a signal transduction pathway
[18].
Pathway analysis shows the pathways linked with the
fifteen-marker panel are signaling, hemostasis, hormone,
and immune system (Additional file 1), which are con-
sistent with previous findings [3].
The confusion matrix and common performance
metrics for both the training data set and testing data set
for the 15-marker panel is shown in Table 4. Although the
final accuracy is 73.85% but can be considered as an
improvement if compared to the original accuracy 56.9%.
In addition, the AUC, a comprehensive measurement of
sensitivity and specificity, is improved markedly from 0.56
to 0.8 (Figure 3 and Table 4).
In order to validate our prediction method, we com-
pared the ROCs for the 15-marker panel determined by
the SVM-RFE-CV with the ROCs for 4 best randomly
selected 15-marker panels and 4 worst randomly selected
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Figure 1 Recursive feature elimination with automatic tuning of the number of features selected with cross-validation.
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(Figure 3) using the Enumeration Method for Validation
described in the method section. As shown in the Figure
3, the 15-marker panel determined by the SVM-RFE-CV
(red solid line) has best sensitivity-specificity-tradeoff
performance than others chosen randomly from 42 candi-
date biomarkers.
We also compared the classification and prediction





















































































































Figure 2 15 biomarkers predicting the healthy and breast cancer samples in testing set. X axis is the 15 biomarkers. Y-axis shows the 33
breast cancer and 32 healthy samples (H, healthy, blue; C, cancer, yellow).
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and SVM-RFE-CV (Table 2). All the three algorithms
can have high performance for the training. The perfor-
mances of SVM-RFE and SVM-RFE-CV for the training
set are the same. But there are differences in the num-
ber of genes and the performance for the testing set
between the three algorithms. The SVM method has no
function of feature elimination. The number of genes
selected by SVM-RFE-CV is lower than that selected by
SVM-RFE. In the testing set, the performance of SVM-
RFE-CV is better than SVM-RFE.
We further evaluated our multi-marker panel predic-
tion performance by comparing our results with predic-
tion performance in previously published findings.
Sharma et al. identified a panel of 37 genes that per-
mitted early detection with the classification accuracy of
82% [4] and Aaroe et al. identified a set of 738 differen-
tially expressed probes that achieved an estimated predic-
tion accuracy of 79.5% with a sensitivity of 80.6% and a
specificity of 78.3% [3]. Considering their methods were
not applied to independent testing sets randomly sepa-
rated from training set but used k-fold cross validation
where the original sample was randomly partitioned into
k subsamples and of the k subsamples, a single subsample
was retained as the validation data for testing the model,
and the remaining k - 1 subsamples were used as training
data, our prediction performance actually outperformed
them (Precision = 100%, Accuracy = 100%, Sensitivity =
100%, Specificity = 100%). We believe our approach is a
significant success, considering that we only used fifteen
gene markers in a panel to achieve the prediction perfor-
mance (AUC = 0.8, Precision = 74.29%, Accuracy =
73.85%, Sensitivity = 76.47%, Specificity = 70.97%).
Lastly, we investigated the effect of qvalue’s threshold
on the results. We obtained 5 markers in the training
set with qvalue < 0.001 and 1454 markers with qvalue <
0.1. For qvalue < 0.001, 3 markers were chosen With
SVM-RFE-CV and produced the prediction performance
of AUC = 0.5; for qvalue < 0.1, 16 markers were chosen
With SVM-RFE-CV and produced the prediction per-
formance of AUC = 0.78. Our results show that the
qvalue < 0.01 has the best prediction performance with
the SVM-RFECV.
Conclusions
We developed an integrated computational approach
that addressed a challenging multi-panel biomarker
development problem in the early detection of breast
cancer in peripheral blood. The approach combined
Table 3 gene expressions changes in 15-marker panel.
ProbeID Genesymbol GeneID direction qvalue
131318 FAM135A 57579 up 0.00775
134303 NOD1 10392 down 0.00995
146885 POMT2 29954 down 0.00459
154366 LEFTY2 7044 up 0.00928
155372 WISP1 8840 down 0.00197
162446 FABP1 2168 up 0.00735
167465 POLR3A 11128 down 0.00754
167529 ICA1 3382 down 0.00368
172360 TMED8 283578 up 0.00582
189547 C5orf20 140947 down 0.00941
206647 ALG10 84920 down 0.00050
210406 SLC33A1 9197 down 0.00483
211808 PLCG1 5335 down 0.00317
222602 LMOD3 56203 up 0.00508
230936 FLJ44635 392490 up 0.00773
Table 4 prediction result for the 15-marker panel
Training set Testing set
Predicted Cancer Normal Cancer Normal
Cancer 33 0 26 9
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recursive feature elimination of SVM with cross-valida-
tion. It automatically learned non-linear relationships
between features and outcomes to generate the optimal
predictive model with the least number of features,
which achieved AUC = 0.80 performance with a sensi-
tivity of 76.47% and a specificity of 70.97% in the testing
data set of 34 women with breast cancer and 31 healthy
women controls.
The SVM-RFE based on cross-validation is able to
identify the optimal multi-markers panel with the least
number of genes. It can filter irrelevant, tissue-specific
genes from those related to malignancy. It also identifies
gene expression patterns related to severity of disease. It
is an effective method for finding markers implicated in
cancers. In the future, we will follow up with biological
experiments to validate these biomarkers we identified
with our collaborators.
Additional material
Additional file 1: Pathway analysis for the fifteen-marker panel.
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RECEIVER OPERATING CHARACTERISTIC (ROC)
Figure 3 Our 15-marker panel compared to 4 best randomly selected 15-marker panels (solid lines, out of 42 candidates) and 4 worst
randomly selected 15-marker panels (dotted lines, out of 42 candidates). The 15-marker panel was compared with the best four 15-marker
panels (solid lines) and the worst four 15-marker panels (dotted lines) which were randomly selected out of the 42 candidates.
Zhang et al. BMC Medical Genomics 2013, 6(Suppl 1):S4
http://www.biomedcentral.com/1755-8794/6/S1/S4
Page 9 of 10
This article has been published as part of BMC Medical Genomics Volume 6
Supplement 1, 2013: Proceedings of the 2011 International Conference on
Bioinformatics and Computational Biology (BIOCOMP’11). The full contents
of the supplement are available online at http://www.biomedcentral.com/
bmcmedgenomics/supplements/6/S1. Publication of this supplement has
been supported by the International Society of Intelligent Biological
Medicine.
Author details
1Department of Academic and Institutional Resources and Technology,
University of North Texas Health Science Center, Fort Worth, TX, USA.
2Department of Forensic and Investigative Genetics, University of North
Texas Health Science Center, Fort Worth, TX, USA. 3Rush University Cancer
Center, Rush University Medical Center, Chicago, IL 60612, USA. 4Department
of General Surgery and Immunology and Microbiology, Rush University
Medical Center, Chicago, IL 60612, USA. 5Department of Internal Medicine
and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
Published: 23 January 2013
References
1. Zhang F, Chen JY: Discovery of pathway biomarkers from coupled
proteomics and systems biology methods. BMC genomics 2010, 11(Suppl
2):S12.
2. Polyak K: Breast cancer: origins and evolution. J Clin Invest 2007,
117(11):3155-3163.
3. Aaroe J, Lindahl T, Dumeaux V, Saebo S, Tobin D, Hagen N, Skaane P,
Lonneborg A, Sharma P, Borresen-Dale AL: Gene expression profiling of
peripheral blood cells for early detection of breast cancer. Breast cancer
research: BCR 2010, 12(1):R7.
4. Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P, Berghagen H, Jensen M,
Kristiansen L, Moen C, Zaka A, et al: Early detection of breast cancer
based on gene-expression patterns in peripheral blood cells. Breast
cancer research: BCR 2005, 7(5):R634-644.
5. Li W: How many genes are needed for early detection of breast cancer,
based on gene expression patterns in peripheral blood cells? Breast
cancer research: BCR 2005, 7(5):E5.
6. Guyon I, Weston J, Barnhill S, Vapnik V: Gene Selection for Cancer
Classification using Support Vector Machines. Mach Learn 2002, 46(1-
3):389-422.
7. Storey JD, Tibshirani R: Statistical significance for genomewide studies.
Proc Natl Acad Sci USA 2003, 100(16):9440-9445.
8. Vapnik VN: Statistical Learning Theory. Springer, NY 1998.
9. Fan Z: A neural network approach to multi-biomarker panel
development based on LC/MS/MS proteomics profiles: a case study in
breast cancer. 2009, 1-6.
10. Zhang F, Drabier R: IPAD: the Integrated Pathway Analysis Database for
systematic enrichment analysis. BMC Bioinformatics 2012, 13(14).
11. da Silva Correia J, Miranda Y, Austin-Brown N, Hsu J, Mathison J, Xiang R,
Zhou H, Li Q, Han J, Ulevitch RJ: Nod1-dependent control of tumor
growth. Proceedings of the National Academy of Sciences of the United States
of America 2006, 103(6):1840-1845.
12. Hernandez-Vargas H, Ouzounova M, Le Calvez-Kelm F, Lambert MP, McKay-
Chopin S, Tavtigian SV, Puisieux A, Matar C, Herceg Z: Methylome analysis
reveals Jak-STAT pathway deregulation in putative breast cancer stem
cells. Epigenetics: official journal of the DNA Methylation Society 2011,
6(4):428-439.
13. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP: Elevated levels of
connective tissue growth factor, WISP-1, and CYR61 in primary breast
cancers associated with more advanced features. Cancer research 2001,
61(24):8917-8923.
14. Davies SR, Watkins G, Mansel RE, Jiang WG: Differential expression and
prognostic implications of the CCN family members WISP-1, WISP-2, and
WISP-3 in human breast cancer. Annals of surgical oncology 2007,
14(6):1909-1918.
15. De Santis ML, Hammamieh R, Das R, Jett M: Adipocyte-fatty acid binding
protein induces apoptosis in DU145 prostate cancer cells. Journal of
experimental therapeutics & oncology 2004, 4(2):91-100.
16. Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M: Expression
patterns of fatty acid binding proteins in breast cancer cells. Journal of
experimental therapeutics & oncology 2005, 5(2):133-143.
17. Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C,
Iezzi M, Lattanzio R, Piantelli M, et al: Phospholipase Cgamma1 is required
for metastasis development and progression. Cancer research 2008,
68(24):10187-10196.
18. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL:
Elevated content of the tyrosine kinase substrate phospholipase C-
gamma 1 in primary human breast carcinomas. Proceedings of the
National Academy of Sciences of the United States of America 1991,
88(23):10435-10439.
doi:10.1186/1755-8794-6-S1-S4
Cite this article as: Zhang et al.: Recursive SVM biomarker selection for
early detection of breast cancer in peripheral blood. BMC Medical
Genomics 2013 6(Suppl 1):S4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. BMC Medical Genomics 2013, 6(Suppl 1):S4
http://www.biomedcentral.com/1755-8794/6/S1/S4
Page 10 of 10
